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ABSTRACT: In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK,
held an international conference with the aim of discussing some key questions around discovering new medicines for infectious
diseases and a particular focus on diseases aﬀecting Low and Middle Income Countries. There is an urgent need for new drugs
to treat most infectious diseases. We were keen to see if there were lessons that we could learn across diﬀerent disease areas and
between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery,
translational, and clinical development processes. We started with an introductory session on the current situation and then
worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies,
drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.
The general introductory session gave the background to thediseases and the problems involved,1 which was started by
Nicholas White. There is a very serious inequity in health care
across the world. Child mortality across the world is inversely
correlated to health spending per capita. Infectious diseases are
still a major cause of mortality and morbidity and, globally, are
the second leading cause of death; respiratory and diarrheal
diseases as the major contributors, followed by tuberculosis and
HIV. Treatments for many of these diseases are far from
satisfactory, with many drugs currently in use dating from early
in the 20th century, being essentially poisons; for example,
arsenic used to treat sleeping sickness and antimonials, for
leishmaniasis. Successes have been seen in some areas, a primary
example being HIV-AIDS, which used to be a “death sentence”.
There are now eﬀective treatments that have been made
available to ∼60% of those infected with HIV, greatly extending
life expectancy. However, many infected individuals are unaware
of their status, meaning that many infected people continue to
spread the disease. In other cases, the situation is static
(tuberculosis) or worsening (malaria); although distribution
of insecticide treated bed nets and the use of artemisinin-based
antimalarials are thought to have saved 6.8 million lives, case
numbers globally are currently increasing again. For some
diseases, such as hepatitis B and hepatitis C, which aﬀect huge
numbers of people, there are drugs available, but they are outside
the budget of most patients and health care providers. Bacterial
infections remain a huge problem, which is exacerbated by the
rise of antimicrobial resistance (AMR), which has a massive
negative eﬀect on global health and the economy. AMR needs to
be approached on multiple levels. What used to be considered
“last resort” antibiotics are widely used in pigs and chickens, for
example, so better stewardship is required. The economic model
for antibacterial drug discovery is broken and needs to be
changed to encourage the pharmaceutical industry to invest in
the development of new treatments. Newly emerging diseases,
such as SARS, “bird ﬂu” (H5N1 with mortality rates of
approximately 50%), MERS, and Ebola, and these types of
outbreaks, potentially with increased transmissibility, remain
major threats.
There are relatively few “players” in the discovery of new
drugs for neglected diseases, as discussed by Paul Herrling.
These include some PDPs (Product Development Partnerships)
and NGOs (Non-Governmental Organizations) such as
Medicines for Malaria Venture (MMV), Drugs for Neglected
Diseases initiative (DNDi), and the TB Alliance. There are
several University-Academic groups and several pharmaceutical
companies that have institutes dedicated to global health and
have drug discovery programs, and other pharmaceutical
companies are giving signiﬁcant resources. The Wellcome
Trust, the Bill and Melinda Gates Foundation, and the NIH also
make substantial contributions to Research and Development.
However, the combined resources from the public, charitable,
and private sectors, amounting to around $1 billion annually (for
NTDs, malaria, and TB), pale in comparison with funds
allocated to the development of drugs for the developed world
conditions (annual BioPharma R&D spending is around $160
billion) and do not satisfy the clinical need.
With increased investment in drug discovery for neglected
diseases has come a better understanding of the respective drug
discovery paths. For dengue for example, it has become clear
that target-based approaches are very challenging, while
phenotypic screening has been more successful. In TB (and
many other diseases), the need for pathophysiologically relevant
in vitro assays to ensure correlation between in vitro and in vivo
(animal models) models and patients has been shown to be
critical. For instance, routine addition of glycerol to in vitro anti-
TB screens to increase growth rates yielded several false positive
hits, due to the nonphysiological interplay between glycerol
metabolism and the inhibitors.2 In the case of malaria,
phenotypic screening against parasites in human red blood
cells appears to be physiologically relevant as several compounds
discovered in this assay are now in clinical development;
however, assays looking at diﬀerent life stages (blood stage
forms, liver schizonts, gametocytes, hypnozoites) are required to
understand fully the clinical potential of new inhibitors.
Subsequent identiﬁcation of the molecular targets for some of
these malaria compounds has further increased the oppor-
tunities to ﬁnd compounds with suitable properties for clinical
development.
In addition to the drug discovery and development process,
the search for new medicines for neglected diseases should also
take into account the environmental, cultural, and social
environment of those aﬀected by these diseases and their access
to healthcare. Finally, the main goal of this research is new
medicines not publications. Publications are important but
should not be allowed to drive the agenda.
By way of example of the challenges in neglected disease
clinical trials, Shyam Sundar gave an overview of ongoing work
on clinical trials for visceral leishmaniasis. This disease, fatal if
left untreated, predominantly aﬀects people living in India, East
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Africa, and South America but is also endemic in several
European countries. A number of drugs are available, including
antimonials, amphotericin B, miltefosine, and paromomycin.
However, antimony is highly toxic, as is amphotericin B, unless
in the liposomal formulation, which is very expensive, and
miltefosine requires a 28-day treatment course and is
teratogenic. Trials of combination treatments using existing
drugs are underway, but there are signiﬁcant diﬀerences in the
eﬃcacy of these therapies from one region to another. Particular
challenges in eliminating visceral leishmaniasis include post kala-
azar dermal leishmaniasis, which can occur after the initial
infection has been treated, constituting a transmission reservoir;
these patients often reject the relatively toxic treatment options.
In addition, HIV−visceral leishmaniasis coinfection is mutually
reinforcing, diﬃcult to treat, and common in some areas. The
long-term aim is to develop new drugs and new combinations for
visceral leishmaniasis.
At the conference, we also wanted to highlight the importance
of public engagement and increasing awareness of neglected
tropical diseases. Toward that end, artist Jen Southern described
a public engagement and contemporary art project, Para-Site-
Seeing, created in collaboration with Rod Dillon (entomologist/
microbiologist studying sandﬂy transmission of Leishmania in
Brazil3) realized as part of both Scotland’s NEoN Digital Arts
Festival [www.northeastofnorth.com] and the LifeSpace
Science Art Research gallery program [lifespace.dundee.ac.uk].
The multispecies relationships of Leishmania can be understood
on both microscopic and global scales, and the project cites
Leishmania research within geographical, cultural, and social
histories. It communicates to audiences, in an engaging and
accessible way, the journey of Leishmania, all told from the
perspective of the parasite through a series of ﬁctional travel
blogs shared on social media (using Twitter, Instagram, and
YouTube). Visitors to both the gallery and the online para-site-
seeing.org Web site can follow the story of the parasite in
photographs, poetry, video, and installations, in the gut of the
sandﬂy, across the world, across the lab, and in its relationship
with the drugs being developed to eliminate it.
■ CLINICAL DEVELOPMENT AND CONNECTIVITY TO
THE PRECLINICAL SITUATION
Clinical development of candidate drugs takes a long time, costs
a lot of money, and has a high attrition rate. Advances that can
speed up the clinical trials process and provide increased
understanding, such as why drugs work or fail, will be invaluable
for infectious diseases, particularly where the patient popula-
tions are in areas with limited facilities for conducting clinical
trials. The regulatory agencies (Food and Drug Administration
[FDA] and European Medicines Agency [EMA]) are viewed as
highly amenable and progressive in their thinking but
consultation should begin very early on in the process. However,
innovation is sorely needed to improve the economic model and
to indicate direct clinical beneﬁts.
Clifton Barry described work on tuberculosis (TB). TB
continues to be a major problem worldwide with: at least 1.5
million deaths per year; a huge proportion of the world
population latently infected; rapidly rising levels of drug resistant
TB; long and complex treatment regimens. Current treatments
typically require 6 months of therapy. The disease is further
complicated by the presence of intracellular and extracellular
bacteria, some in aerobic conditions and some in anaerobic
environments. There are also bacteria found in caseous
granulomas, where many drugs cannot penetrate. Further,
there are also slow growing forms (“persisters”) that are less
susceptible to drugs. The complexity of human disease means
that it is challenging to ﬁnd an animal model that is predictive of
human disease. Indeed, several expensive clinical trials have
failed in the past.
Recently, the marmoset (Callithrix jacchus) has been used as a
model, which is naturally infected with TB and more closely
replicates human disease as well as treatment outcomes. Using
linezolid, for example, TB lesions have been monitored by PET/
CT (positron emission tomography/computed tomography)
scanning in this model. This shows that the disease is very
dynamic. From this, it is possible to see that treatment does not,
and may not need to, give rise to complete resolution of lesions,
but it pushes the equilibrium to a level where the immune system
can re-establish control. This model for understanding disease
progression has now been extended to human clinical studies.
The imaging studies give a much clearer understanding of
disease progression than measuring the numbers of bacteria in
sputum, for example. Imaging allows one to study the eﬀects of
new treatments on individual lesions. This oﬀers the possibility
of having a major impact on phase 2 clinical studies.
James McCarthy presented the many beneﬁts of malaria
Volunteer Infection Studies (VIS). In this human challenge
model, healthy volunteers are injected with Plasmodium-infected
erythrocytes, resulting in a well standardized course of
parasitaemia with little or no illness. Volunteers are treated
with experimental drugs on day 8 with the collection of both
pharmacokinetic data and pharmacodynamic data (parasitemia
levels derived using PCR). This model allows early pharmaco-
kinetic/pharmacodynamic (PK/PD) characterization of new
drugs and is ideally suited to investigate new drug combinations.
As such, VIS are a game changer for malaria clinical
development.
In the case of Chagas’ disease, the current burden of infection
is primarily the chronic, indeterminate stage. This occurs after
the initial acute infection. The infected subject experiences little
or no clinical symptoms, and the parasites are diﬃcult to detect
in the blood but persist in various tissues. The disease is endemic
in the Americas but is also found in Spain and several countries
in Europe, primarily due to population ﬂows. Isabela Ribeiro
described a number of clinical trials using benznidazole,
nifurtimox, and the CYP51 inhibitors posaconazole and
fosravuconazole. On the basis of trial data generated in the
1990s, benznidazole was recently (2017) approved by the FDA
for use in children aged 2 to 12 years with a 60-day dosing
regimen. A more recent trial with benznidazole (BENDITA:
NCT03378661) suggests that a shorter regimen of benznidazole
may retain eﬃcacy, while signiﬁcantly reducing adverse side
eﬀects that currently lead to frequent treatment discontinuation.
Trials assessing the CYP51 inhibitors all failed to show sustained
parasite clearance.4,5 More encouragingly, a recent trial testing
the sleeping sickness drug fexinidazole (DNDi-CH-FEXI-001:
NCT02498782) showed high sustained parasite clearance rates
but also unexpected toxicity. A follow-up trial with lower doses is
now ongoing in Chagas’ disease patients (FEXI12:
NCT03587766). Assessment of parasite clearance in clinical
trials typically involves multiple PCR samplings to detect
parasite DNA in blood; however, parasite densities in blood are
typically very low, and negative PCR results do not equate to
cure. This presents particular challenges in the chronic stage,
where reservoirs of parasites may persist in inaccessible tissues
and cardiac involvement may be present prior to therapy. To
increase the sensitivity of the PCRmethod, multiple samples are
ACS Infectious Diseases Viewpoint
DOI: 10.1021/acsinfecdis.9b00371
ACS Infect. Dis. 2020, 6, 3−13
5
tested at multiple time points, but the lack of a simpler, more
robust measure of cure remains a key issue to date. In the case of
Chagas’, on one hand, we need shorter trials, but on the other,
long-term follow-up may be needed for the qualiﬁcation of
markers and the correlation to clinical impact.
William Hope described aspects of clinical development of
antibacterials. Late-stage clinical trials for antibacterials are
currently too costly, and biomarkers are often poorly predictive
of clinical beneﬁt. Antibacterial stewardship will be particularly
important to reduce the widespread and proﬂigate use of
valuable drugs that could otherwise have an extended lifespan.
New antibacterial drugs need to be novel and address an unmet
clinical need. Carefully planned clinical trials to demonstrate
eﬃcacy and safety are a critical part of the drug discovery
process. Randomized clinical trials are the typical way to
proceed; however, patient recruitment is very diﬃcult,
particularly MDR/XDR patients, at least in high income
countries. A noninferiority study relative to the standard of
care is usually the starting point. As a consequence, relatively
prevalent complicated urinary tract infections are usually used
for the initial studies. Other types of infection can be more
challenging, because many of these patients are very sick, already
having been exposed to antibiotics and may have very diﬀerent
PK and PD relative to healthy volunteers.
■ COMBINATION THERAPY: CLINICAL AND
PRECLINICAL SELECTION
For many infectious diseases, combination therapy is used or is
being considered. This can be for a variety of reasons: to reduce
the risk of resistance; to increase the eﬃcacy through synergy or
additive action; to tackle pathogens in multiple states and/or
locations within the body; to broaden the spectrum of activity;
to potentially reduce toxicity through reduced dosing. The
selection of combinations can be very challenging, however, and
potential drug−drug interactions must also be considered.
Didier Leroy described how combination therapies are now
standard for malaria treatment, but many currently accessible
combinations contain artemisinin, meaning that artemisinin
failure would have a major detrimental impact on multiple
therapies. As noted above, VIS may facilitate the relatively rapid
testing of a number of new drug combinations against malaria.
The humanized mouse model of malaria, involving SCID mice
transfused with human red blood cells (Plasmodium falciparum
does not infect mouse red blood cells), allows for testing of even
greater numbers of combinations, which may be prioritized for
testing based on in silico predictions. Between March 2017 and
April 2019, 23 combinations have been studied for PK/PD
relationships by the team of Dr. Inigo Angulo-Barturen (CEO of
the Art of Discovery in Bilbao), who pioneered the industrialized
HuSCIDmouse model for malaria. This approach is successfully
revealing examples of both antagonism and synergy. Notably,
dosing is typically applied at levels that yield recrudescence
within 60 days such that drug eﬃcacy can be compared in a
quantitative manner.
Checkerboard or isobologram analyses are typically used to
assess drug−drug interactions in vitro and their synergistic or
antagonistic impacts on pathogen viability. Bree Aldridge
described that there are now new, more eﬃcient sampling and
scoring methods that allow assessment of higher-order
combinations, speciﬁcally applied to the TB assay, such as
DiaMOND (diagonal measurement of n-way drug interac-
tions).6 These assays are now being applied to TB cultures in
stress conditions rather than in “rich media” in the hope that the
outputs will be more readily translated to in vivo eﬃcacy. As
noted above, however, TB tissue distribution, persisters, and
dosing regimen and time frame are all factors that must be
considered during the progression of potential combinations.
John Pottage discussed combination treatment in HIV
infection. There are currently 1.8 million new cases of HIV
infection per year. Since therapy is life-long, toxicity can be
cumulative, so a key goal is to reduce dosing and long-term
exposure. For HIV, approximately 40 medicines have emerged
during a total of 38 years of the epidemic, but a cure has been
documented for only two individuals following bone marrow
transplant; latent reservoirs remain a major challenge.
Combinations of nucleoside analogues, protease inhibitors,
and integrase inhibitors are highly eﬀective, but the GEMINI
trials (NCT00105079) indicated that two-drug combinations
can be equally eﬀective compared to three-drug combinations.
The question here is whether two-drug combinations will
provide suﬃcient mitigation against the emergence of resistance
over a long period of time. Notably, clinicians favor a daily oral
formulation, whereas many patients favor a monthly parenteral
administration. This has led to the introduction of several long
acting parenteral antiretroviral agents into clinical development.
OlenaMoshynets reported on the combination of a macrolide
and colistin for treatment of carbapenem-resistant infections
due to Klebsiella pneumoniae. The rationale for this study was
that azithromycin is good at preventing bioﬁlm formation in
K. pneumoniae and increases the eﬀectiveness of colistin. Bioﬁlm
formation by bacterial opportunists during an infection process
reduces antibiotic eﬀectiveness.7 Colistin is a toxic antibiotic,
with relatively low eﬃcacy, which requires very high levels of
dosing. It is often dosed with other antibiotics. Some early
clinical data were presented. Speciﬁcally, a combined anti-
bacterial therapy including azithromycin, colistin, and tienam
was applied in two cases of severe sepsis associated with bad
prognosis caused by carbapenem-resistant K. pneumonia. The
infection was completely eradicated in both cases. The
experimental treatment was performed by Head of the
Department of Surgical Treatment of Infective Endocarditis of
Amosov National Institute of Cardiovascular Surgery, A.
Krykunov (Moshynets and Krykunov, manuscript in prepara-
tion).
Maria Jose Lafuente reported on combination studies using
Plasmodium falciparum. The tools available include in vitro
isobolograms, in vitro PRR (parasite reduction ratio) assay, and
the in vivo humanized mouse model. The time to recrudescence
is used as the main PD end point, looking for an increase in time
to recrudescence longer than that of each of the individual
components.
■ PK/PD STUDIES AND ANIMAL MODELS
Animal models of infection can be highly valuable in optimizing
PK/PD before progressing into the clinic. However, it is critical
that the animal models developed should be representative of
human disease.
There were two talks on cryptosporidiosis from Wes van
Voorhis and Ujjini Manjunatha. The GEMS study8 highlighted
cryptosporidiosis as the second most common cause of diarrhea
in children and of death in toddlers, and the MAL-ED study9
highlighted the link to stunting andmalnutrition. The only FDA-
approved drug for cryptosporidiosis is nitazoxanide, but this
drug provides only a 34% improvement over a placebo and is
unsuitable for HIV-infected individuals or for children under 1
year old. The current Target Product Proﬁle indicates the need
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for a therapy that is suitable for babies of less than 6 months, safe
for presumptive disease (given the diﬃculties with current
point-of-care diagnosis), inexpensive, and available in a liquid
and stable formulation. A treatment for cattle is also desirable.
Mice (Cryptosporidium parvum), calf (C. parvum), and piglet
(C. hominis) models of cryptosporidiosis are used preclinically.
Two compound series were described: a series of bumped kinase
inhibitors (BKIs) being developed by the University of
Washington10−12 and PI(4)K inhibitors being developed by
Novartis.13 For both of these series, eﬃcacy in mouse models of
infection is not dependent on plasma levels of compounds. In
the case of the BKIs, gastrointestinal (GI) epithelial cell
concentrations in the terminal ileum and cecum, where
cryptosporidium predominately replicates, can be used to
predict in vivo eﬃcacy. BKI GI ileocecal epithelial concen-
trations can bemodeled byGastroPlus, and these modeled levels
have been conﬁrmed in mice during a time course after
administering BKIs and harvesting organs for tissue levels post-
mortem.14 Interestingly, eﬄux by Pgps (P-glycoprotein eﬄux
pumps) appears to reduce eﬃcacy.15 BKIs that are eﬀective in
mice have been shown to dramatically reduce diarrhea and
parasite excretion in both calf16,17 and piglet models18 of
established Cryptosporidium infection.
The Cryptosporidium PI(4)K inhibitors were identiﬁed from a
phenotypic screen of a focused new chemical library, and
CpPI(4)K has been validated as a promising molecular target in
both immunocompromised mouse and neonatal calf models.13
The lead candidate displays low clearance and medium to low
oral bioavailability across a range of species. Mass spectrometry
imaging (MS-Imaging) is a label-free technique used to visualize
the spatial distribution of compounds by their molecular masses.
MS imaging in mice showed that the compound is localized in
the gastrointestinal tract. Intravenous dosing of the compound is
not eﬃcacious, unlike the case of oral delivery, despite similar
systemic exposure, indicating that systemic exposure alone is not
suﬃcient for eﬃcacy.
Soft drugs (SD) are commonly used to limit systemic
exposure, thereby enhancing the therapeutic margin. An oral
soft-drug approach, where systemic exposure was limited
through fast metabolism after absorption, demonstrated that
GI exposure is necessary and suﬃcient for eﬃcacy in the
immunocompromised mouse model (Manjunatha et al.
unpublished results). As an alternative to the soft-drug
approach, compounds with the right balance of properties
(permeability, solubility) can be developed with limited
systemic exposure, while retaining suﬃcient permeability to
access parasites.
In patients, watery diarrheal symptoms and shorter GI transit
time may reduce eﬃcacy; thus, eﬃcacy in the more clinically
relevant calf model and in the controlled human infection model
is important. For the soft-drug approach, it will be important to
consider the therapeutic window in the target patient
populations: diarrheal patients under 2 years; children with
severe acute malnutrition (SAM); immunocompromised
children due to HIV infection or malnutrition with reduced
metabolic capacity, who are likely to have reduced metabolic
activity.
PK/PD for cryptosporidiosis (at least in the mouse, calf, and
piglet models of disease) is driven by gastrointestinal tract
distribution rather than systemic distribution, given that the GI
tract may be the sole relevant niche for the parasite for diarrhea
and GI tract dysfunction, such as environmental enteric
dysfunction and subsequent malnutrition and stunting. Though
the primary site of Cryptosporidium infection is epithelial cells in
the small intestine, infections outside the GI tract have been
reported in humans,19 mainly in chronic immunocompromised
HIV-positive cryptosporidiosis patients. However, such reports
in children are sparse, and it remains to be seen how relevant a
recently reported Cryptosporidium respiratory infection is to
intestinal cryptosporidiosis, diarrhea, and a possible persistence
in the GI.19
Formalaria, wheremany compounds are in the drug discovery
pipeline, valid PK/PD models are essential to prioritize
compounds for development. Nathalie Gobeau described how
the models are established ﬁrst on the basis of eﬃcacy and PK
data from the humanized SCIDmouse model, and then together
with the predicted human PK, predicted human doses are
calculated. Compounds with the lowest predicted dose are
prioritized for testing in the above-mentioned human challenge
trials, which allows further tuning of the PK/PD model. It is
critically important in malaria therapy to predict appropriate
combination partners, and both PK and PD interaction models
are used to rank potential combinations. The top combinations
are then tested once again in the VIS model (see above).
In liver stage malaria (pre-erythrocytic development),
Thomas Spangenberg reported that the activity on the
Plasmodium berghei infected liver cell spheroids of a clinical
compound could be correlated with the corresponding in vivo
eﬃcacy mouse model by comparing IC99 (in vitro) and average
systemic concentration (in vivo) values.20
The cryptosporidiosis case clearly shows that systemic blood
exposure is not always the relevant PK parameter and that drug
exposure for the infectious organism will depend on the location
of the organism in the human host. Thomas Spangenberg
discussed PK/PD models in schistosomiasis. Schistosoma
mansoni worms live in the mesenteric veins, and systemic
plasma exposure of praziquantel in the S. mansonimouse model
is not predictive of eﬃcacy. However, estimated portal vein drug
concentrations do predict the eﬃcacy of praziquantel, indicating
that exposure prior to the ﬁrst pass metabolism in the liver is
critical. This was supported through the use of a cytochrome
P450 metabolism inducer, which resulted in much lower
systemic exposure but no reduction in eﬃcacy of praziquantel.21
In some pathogens, compound access can be restricted,
compounds eﬄuxed or metabolized, aﬀecting compound
exposure within the pathogen. Understanding this is of key
importance to understand PK studies. Caitlin Taylor outlined an
approach usingMycobacterium tuberculosis spheroplasts that lack
a mycomembrane and peptidoglycan. The concept is to identify
potentially promising inhibitory compounds that are not
normally taken up. In turn, this knowledge will inform current
eﬀorts to understand drug transport and uptake in mycobacteria
with the aim of facilitating the development of more general
strategies for anti-TB drug delivery. Since small changes in the
structure of a compound can have a signiﬁcant impact on
activity, her work exploits click chemistry using azide-derivatized
compounds developed by a collaborator (Dr. Mark Blaskovich,
University of Queensland) to establish intracellular localization
within the (myco)bacterial cell.
■ DRUG DISCOVERY PATHWAYS
In this session, Manu De Rycker discussed drug discovery
pathways for kinetoplastid infections, Jennifer Keiser, helminth
infections, Valerie Mizrahi, tuberculosis, and Lynn Silver,
bacterial infections. There were common challenges among
these disease areas.
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For many of these diseases, the preclinical development
pathway is poorly understood and in need of further
development. It is important to deﬁne the assays that are
representative of human disease and can be used to triage
compounds and guide the chemistry optimization. This is
particularly the case where there are no current clinical
treatments or the only drugs are reactive or form reactive
intermediates. A particular challenge is heterogeneity in
infectious organisms. This is very obvious in helminth infections
where diﬀerent developmental stages as larvae and adult worms
might occur in infected people. Building in vitro assays that can
assess all these stages is challenging, in particular for the adult
worms, which typically need to be isolated from animals,
severely limiting the throughput of any assays. Usually, more
easily accessible stages are used for primary high-throughput
screening, with the risk that compound activity will not translate
to all disease-relevant stages.22 Other pathogens, such as
Mycobacterium tuberculosis and most protozoan parasites, are
also present in multiple diﬀerent states.
Persister organisms pose another challenge.23 Persisters are
usually deﬁned as forms that are less susceptible to drug action,
often due to some form of quiescence. Persister bacteria are well
described in TB and divided into class I persisters, a small
population that occurs stochastically, and class II persisters,
where themicroenvironment triggers the persister state in a local
population. Recreating class I in vitro may not be possible, but
under certain conditions (such as hypoxia or other conditions
that induce a state of nonreplication), class II persisters can be
obtained and used in phenotypic screens.24 Recently, persister
parasites were also identiﬁed in vitro for Trypanosoma cruzi, and
the ability to kill these appears to be the best in vitro predictor of
in vivo eﬃcacy,25,26 emphasizing the need to dedicate suﬃcient
time and resources to developing appropriate in vitro assays.
Another issue is that, for many infectious organisms,
phenotypic hits often target a small set of common targets.
For example, for TB, cell wall inhibitors and Qcrb inhibitors are
frequently identiﬁed,27 whereas the ergosterol biosynthetic
pathway enzyme CYP51 is a very frequent target in T. cruzi
phenotypic screens. To contend with this, secondary assays need
to be put in place to quickly identify such hits as compounds
with novel modes of action are more desirable. Alternatively,
primary screens can be adjusted to avoid ﬁnding hits for these
promiscuous targets, especially those with a history of failure in
clinical trials, such as T. cruzi CYP51.
Another consideration is that in vitro assays can never fully
reproduce the in vivo situation and that key diﬀerences may exist
between animal models and humans. In this respect, the in vivo
microenvironment plays a key role and can trigger alternative
metabolic states, provide bypass metabolites, or change
expression of key targets. As such, a target that is essential for
growth in vitromay not be required by all disease-causing stages.
This brings us to the long-standing question of target versus
phenotypic-based drug discovery approaches. Phenotypic hits
have some key advantages, in particular that polypharmacology
may drive their activity, potentially resulting in higher eﬃcacy or
lower resistance potential. Target-based programs have the key
advantage of allowing rational design of inhibitors but may yield
compounds with a higher likelihood of resistance, although this
risk is attenuated when using such compounds in combinations.
There is value in both approaches, and the choice between them
will depend on many factors, including resistance generation
potential of the infectious organism, the availability of disease-
relevant validated targets, and the availability of appropriate cell-
based assays.
Helminth infections are poorly treated and lead to short-term
issues such as diarrhea, fatigue, and anemia. The long-term
consequences include malabsorption of food and growth and
cognitive retardation. Over 250 million people are infected with
schistosomiasis. The only drug registered to treat this is
praziquantel, and there is concern over resistance and hence a
need for a new medicine. The parasite has a complex life cycle,
and it is not suitable for high throughput screening. A screening
cascade has been established, starting with the schistosomula,
which has the highest throughput. Actives are then screened
against the juvenile and adult worms,22 which are much lower
throughput assays. However, there is good interlaboratory
conﬁrmation of activity. Several screens have been conducted
using the malaria or pathogen box fromMMV, for example.28 In
addition, there are several interesting starting points from
various sources; e.g., lead compounds investigated several
decades ago at Hoﬀmann La-Roche are currently being
studied.29 There are also a number of species of soil-transmitted
helminths (STH) that cause human disease: principally Ascaris
lumbricoides, Trichuris trichiura, and hookworms (Necator
americanus and Ancylostoma duodenale). It is estimated that 1.5
billion people are infected with one or more STH, and only
limited treatment options lacking a broad spectrum of eﬃcacy
are available.30 Similar screening cascades have been developed
for these pathogens. As is the case with schistosomes, these are
low throughput. Unfortunately, there is very limited drug
discovery ongoing against helminths, despite the immense
clinical need.
Antibacterial drug discovery is proving very challenging, and
the growing problem of antimicrobial resistance (AMR) is well
documented. Despite the rise in antimicrobial resistance, the
commercial drivers are low and most large pharmaceutical
companies have pulled out of antibacterial drug discovery. As in
other areas of anti-infectives research, both target-based and
phenotypic approaches have been used. Target-based ap-
proaches have a poor track record for antibacterial drug
discovery, for several reasons. Compounds either are not
taken up by bacteria or are eﬄuxed before they can exert their
eﬀect. Second, use of a single target has a high resistance
potential. The qualiﬁcations for a target are as follows:
• It must be essential for survival of the bacterium both in
vitro and in vivo.
• It must be possible to achieve selectivity compared to the
human homologue, if any.
• It must have a useful antibacterial spectrum of activity.
• The target must be druggable.
• There must be a very low frequency of resistance, and
there must not be existing resistant mutants. Ideally,
targets should be selected where multiple mutations are
required for resistance.
Single target antibacterials will almost certainly need to be
combined with other agents as a ﬁxed dose or standard
combination. This brings challenges, such as matching PK
between the individual agents, and it can be diﬃcult to
demonstrate clinical beneﬁt to the regulators. There are limited
models for testing resistance development; hollow ﬁber
infection models (HFIM) are useful but lack in vivo factors,
while high inoculum animal models are very diﬃcult to achieve.
Another approach is to prepare compounds that target more
than one enzyme; however, this is very challenging from a design
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perspective and is further complicated by issues such as
selectivity compared to human homologues.
Another approach to ﬁnding chemical starting points is
phenotypic screening. However, this tends to have a low hit rate,
probably due to the challenges associated with uptake and eﬄux.
It also appears that chemical libraries screened are not optimal
for the chemical space required for compounds active against
Gram-negative antibacterials.31,32
The entry of compounds into bacteria is potentially complex
and not well understood. The cell envelope contains lipo-
polysaccharides, which are hydrated and repel hydrophobic
molecules. Penetration across the cell membrane is more typical
of diﬀusion across lipid bilayers, requiring a degree of
lipophilicity, which is contradictory to the properties for passage
through the porins. Therefore, diﬀusion is very limited. In some
cases, active transport is found across the plasma membrane. A
Trojan horse strategy has also been used, piggybacking onto a
molecule for active or facilitated transport. Further eﬀorts
should focus on understanding antibacterial drug delivery
routes. Compound eﬄux is another issue, which is poorly
understood and aﬀects many compounds that penetrate the
bacterial envelope, impacting compound levels within bacteria.
Furthermore, there is a potential for metabolism of compounds
by bacteria, and this also needs to be investigated.
Other strategies are being investigated, for example, externally
exposed bacterial targets. Host driven strategies could be
another fruitful area for further development.
TB in particular is a complicated disease, with the bacterium
found in multiple states and with diﬀerent tissue distributions.33
There is a need for new drugs that can tackle problems such as
drug resistance and dramatically shorten the current treatment
regimens, which is 6 months, even for drug sensitive TB. There
are many similarities with drug discovery for Gram-negative
bacterial infections. Target-based approaches are problematic
due to challenges associated with getting compounds into
bacteria, eﬄux, and in the case of TB, metabolism of the
compounds. As with Gram-negative bacteria (and most
infectious diseases), there are very few highly validated drug
targets. In contrast to Gram-negative bacteria, phenotypic
screening has identiﬁed a number of diﬀerent compound series;
however, target deconvolution is complicated.34
■ NEW START POINTS AND TARGETS
In the case of infectious diseases, there are very few robustly
validated drug targets. For many of these diseases, it is also
challenging to identify quality chemical starting points. This is
exacerbated in some disease areas where millions of compounds
have been screened phenotypically, and accessing chemical
matter for screening that occupies a diﬀerentiated chemical
space is becoming increasingly challenging.
Susan Wyllie talked about the work of the Mode of Action
(MoA) group in Dundee, who employ multiple orthogonal
techniques to determine the molecular targets of compounds
that are phenotypically active against kinetoplastid parasites.
Targets identiﬁed in the course of these studies can be
considered as high-value drug targets, since they are associated
with a compound known to kill the parasite. Knowledge of the
molecular target of phenotypically active compounds can
facilitate the drug discovery process:
• It opens up the possibility of target (structure)-based
projects against better validated targets, derisking
medicinal chemistry optimization of compounds.
• It allows identiﬁcation of any human homologues that can
be used to optimize selectivity.
• It can be used to circumvent pharmacokinetic or
toxicological issues using techniques such as scaﬀold
hopping.
• If multiple series work through the same molecular target,
it can assist in portfolio management by providing
information that allows the series to be prioritized.
• It can be used to deprioritize compound series that work
through less attractive mechanisms, allowing resource
reassignment.
• It can assist in the rational selection of compounds for
combination therapy.
The MoA group uses high-throughput genetics, cellular
biology approaches, and proteomics approaches to determine
the molecular targets of compounds. Their experience
demonstrates that no one technique or methodology is suﬃcient
to determine the mechanism of action of every compound or
series; thus the use of multiple, orthogonal, and unbiased
approaches is crucial.
Jacquin Niles has been developing new genetic tools for target
identiﬁcation in malaria. Chemical (recombinant) genetics
approaches are proving very powerful for drug target
deconvolution in Plasmodium falciparum, despite challenges
associated with low transfection eﬃciency and with high
genomic AT bias. An engineered translational switch system
has been used to toggle gene expression up or down. The system
can be used to screen for essentiality and also to assist in target
deconvolution for phenotypic screening hits. tRNA synthetase
inhibitors provide a proof of concept for a synthetic hyper-
sensitivity approach, and further compounds have been
conﬁrmed as on-target with scaling and multiplexing currently
underway.
Natural products remain one of the best sources of anti-
infective drug leads. They contain an enormous chemical
diversity and often exhibit new mechanisms of action.35,36 A key
challenge is identifying novel natural product scaﬀolds that are
likely to have a therapeutic eﬀect and obtain those in adequate
amounts for further development. Jennifer Herrmann discussed
how Myxobacteria are a rich source of novel natural products,
which have diverse biological activities.37 Modern bioinformatic
and genomic approaches contribute to ﬁnding and modifying
these new natural products. The pipeline at Helmholtz Institute
for Pharmaceutical Research Saarland includes screening,
compound isolation and structure elucidation, mode of action,
resistance and biosynthesis studies, scale-up, and targeted
modiﬁcation of interesting candidates. Promising natural
compound classes from Myxobacteria include antibacterial
Cystobactamids exhibiting broad-spectrum activity against all
major multidrug resistant pathogens,38,39 antiﬁlarial Corallopyr-
onins depleting Wolbachia endosymbionts of nematodes
through targeting RNA polymerase,40,41 and antimalarial
Chlorotonils exhibiting activity against all erythrocytic stages
of Plasmodium falciparum including stages responsible for
transmission.42 The application of multidisciplinary method-
ologies supports and accelerates the preclinical development of
natural products in various ways. To name a few examples,
resistance genes and related mechanisms can be identiﬁed using
biosynthetic gene cluster analysis, assisting mode of action
studies.43,44 Semisynthesis is a good route to diversify and
optimize the potency and pharmaceutical properties of
molecules. Heterologous expression systems can signiﬁcantly
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increase product titers to improve natural product supply for
further investigations.45
A group at Novartis Institute for Tropical Diseases has been
working on a program for human African trypanosomiasis, as
outlined by Srinivasa Rao. Their starting point was a phenotypic
screen of >2 million compounds, which gave rise to about 1000
hits that targeted multiple trypanosomatids. These were further
prioritized through a series of assays. Tractable scaﬀolds were
identiﬁed through clustering and identifying clusters with a large
variation in potency (∼3 log units). Further triaging used disease
relevant assays. These included: cidality assays, looking at the
concentration of compound and time to kill; a wash-oﬀ assay to
predict reversibility; early assessment in animal models of
infection; the use of physicochemical properties to optimize
brain penetration. They also found that early identiﬁcation of
the mode of action was important to ensure compounds remain
“on-target”.
Fred Buckner from the University of Washington in Seattle
contrasted target-based and phenotypic approaches. Analysis
from Swinney and Anthony46 indicates that the majority of ﬁrst
in class new medicines are discovered through a phenotypic
approach, while the follow-on compounds are more often
discovered through target-based programs. Starting with the
Target Product Proﬁle is key; in the case of human African
trypanosomiasis (HAT), this includes blood brain penetration.
They triaged compounds from a screen of >700 000 compounds
against the bloodstream-form of T. brucei. Triaging included the
rule-of-ﬁve, as well as avoiding singletons. Exemplars from the
scaﬀolds identiﬁed were investigated for CNS penetration,
leaving nine series. Following hit expansion, three series were
further progressed. Compound series were terminated due to
ﬂat SAR, pharmacokinetic issues, and static rather than cidal
mechanisms of action. This was contrasted with a program
targeting methionyl tRNA synthetase that had the distinct
advantage of being structurally enabled, facilitating preparation
of highly potent and selective compounds. A major challenge is
the CNS penetration.
A presentation from Richard Amewu at the University of
Ghana highlighted the issues of coinfections that are often found
in patients, a particular issue in malaria/TB. He discussed
approaches for the design of compounds that target both
pathogens.
An analysis of current drugs, by Paul Leeson, revealed some
important information about what constitutes a good drug
molecule.47 Over the last 70 years, the average molecular weight
of oral drugs has been increasing. This is in contrast to the clogP,
which has remained reasonably constant (∼2.5), although it has
risen slightly over the past few years, possibly due to the
development of inhibitors of protein−protein interactions. It is
also instructive to see how the properties of molecules change as
the dose in increased.48 It is generally reported that metabolism
and toxicity problems are likely to increase as the MW increases
above 400 Da and the clogP above 4. Therefore, it is important
to see how safety margins are maintained as the dose increases.
With smaller doses (<300 mg), clogP is about 3.0; average MW
is about 360 Da, and about 50% of compounds are basic, while
35% are neutral and 10% are acidic. However, for high dose
compounds (>1000 mg), the average clogP is ∼1; the MW is
about 250 Da, and 45% of compounds are neutral, while 31% are
acidic and 16% are basic.
Optimum physicochemical properties vary from target to
target, due to diﬀerences in the size of the binding site, the
interactions available, and also access to the target in phenotypic
and pathogen screens. There is also a “practice” eﬀect, since
there are large diﬀerences between companies, when comparing
the properties of compounds that are acting on the same target.
This may be due to the culture within the company and how hits
are selected and optimized.49
For oral drugs, the ligand eﬃciency (LE) and lipophilic ligand
eﬃciency (LLE) values show wide variability. However, it is
important to note that the LE and LLE values tend to be greater
for drugs than the mean value of published inhibitors for the
target.50,51 This is true even for drugs and candidate drugs
discovered using phenotypic screens such as antimalarials and
for those in the “beyond rule-of-ﬁve” space. In general, where
there is a low dose of compounds, the improvement of LE and
LLE over the target mean is even higher.
John Overington discussed a number of issues around drug
discovery that have been analyzed using a chemoinformatic
approach. It is important to understand the molecular targets of
drugs and compounds in the pipeline. Looking at antibacterial
drug discovery, there are still relatively few diﬀerent mechanisms
targeted.52 While some drugs target enzymes that are present in
the bacteria but absent in the human host, actually, it is possible
to obtain very good levels of selectivity between bacterial
enzymes and their human orthologues, and we need to be careful
not to discard potentially good targets just because there is a
human orthologue. While overall the physicochemical proper-
ties of antibacterial compounds are diﬀerent from those of
human drugs, there is also an inﬂuence of the target; so, drugs
that target the ribosome often have very diﬀerent physicochem-
ical properties from those that target a typical cytoplasmic
enzyme.53
There are a number of diﬀerent approaches that can be used
for developing drug combinations. From the target perspective,
there can be two diﬀerent active sites on the same target, two
diﬀerent enzymes in the same pathway, or two enzymes in
diﬀerent pathways. From the compound perspective, there can
be single drugs targeting single targets; single drugs targeting
multiple targets; multiple drugs targeting the same target;
multiple drugs targeting multiple targets.
There are a number of ways that “combinations” can be used
to tackle resistance of a particular target. For example, in
switched sequential therapy, there is a change to a drug that is
active against the mutant protein. In “blended therapy”, drugs
that are competitive for the same active site but are active against
diﬀerent mutants are dosed simultaneously.
Finally by mining data from diﬀerent types of assays
(biochemical, cell-based, functional, animal models, DMPK,
and human clinical data), we should be able to improve the
decision making process for when to progress a compound to
further assays and what are the appropriate assays.
■ SUMMARY
Many common themes ran through the presentations. In short,
infectious diseases represent a huge unmet medical need, which
has a much more signiﬁcant eﬀect in Low and Middle Income
Countries. There is a need for new medicines, and the current
investment is insuﬃcient. Furthermore, many of the patients are
malnourished and many have multiple diseases, for example, TB
and HIV coinfection. Many are also children. This complicates
the clinical development and clinical trials and places a high bar
on safety and eﬃcacy.
There is a need for smarter clinical trials to give an earlier read
out of likely eﬃcacy, ideally before being taken to some quite
challenging environments currently used for clinical trials.
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Approaches include using imaging technologies and human
challenge models. There is also a need for biomarkers to assist in
clinical trials for diseases such as Chagas’ disease. Patient
recruitment is not to be underestimated, for example, in the case
of bacterial infections. In many cases, the majority of the patients
are infants and children, and this needs to be factored into the
clinical development of compounds.
Combination therapy is already standard in many disease
areas, and in other areas, it is likely to become more important.
Combination therapy can have multiple facets: improvement of
eﬃcacy, for example, to achieve a single dose cure; broadening
the spectrum of eﬃcacy as for the soil transmitted helminths;
reducing the risk of resistance; dealing with pathogens with
widespread tissue distribution and population heterogeneity.
The selection of combination partners is very challenging.
Ideally, this requires matched PK and that there are no clinically
signiﬁcant adverse drug−drug interactions. It is also important
to make sure that the modes of action of the individual
compounds are compatible (for example, not signiﬁcantly
antagonistic and, where there is population heterogeneity, that
modes of action cover all forms of the pathogen).
Understanding the PK/PD is critical and can help to
understand what is required for a drug. Therefore, the
establishment of animal models of infection that are relevant
to human disease is very important. Knowledge of where the
pathogens are located within the body determines the required
distribution of the compound. Various imaging technologies,
including mass spectroscopy imaging, are under development,
which can address these issues.
For many of these diseases, drug discovery pathways have not
been established. Therefore, the determination of disease
relevant assays and screening cascades is critical. It is important
to develop assays to understand issues such as the susceptibility
of persisters or slow growing pathogens to compounds and
compound uptake and eﬄux from pathogens. The speed of kill
of the pathogens is also an important factor in many cases. The
development of resistance is also a major problem. It is not
always clear what is the correlation between the development of
resistance in the laboratory setting and that in the clinic and also
the ﬁtness cost of individual resistance mechanisms.
Recently, a lot of work has gone into determining drug mode
of action, particularly for antikinetoplastid compounds and
drugs, and this is having a major impact on decision making and
prioritization in the drug discovery process. Attention also needs
to be placed on understanding the physicochemical properties of
the compounds that are drugs from the outset.
Clearly, there are a lot of common challenges in drug
discovery for the diseases covered in this conference, and a
better understanding and know-how in certain diseases (e.g.,
combination treatment in TB and malaria, mode of action
studies in kinetoplastids, and persisters in TB and malaria) are
invaluable to help build development paths for other, less well
understood diseases. Thus, this conference clearly demonstrated
the value of looking across disease areas to ﬁnd parallels, new
approaches, and new opportunities.
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: i.h.gilbert@dundee.ac.uk. Tel +44 1382 386 240.
ORCID
Manu De Rycker: 0000-0002-3171-3519
Frederick S. Buckner: 0000-0001-7796-6477
Jennifer Keiser: 0000-0003-0290-3521
Paul D. Leeson: 0000-0003-0212-3437
Ujjini H. Manjunatha: 0000-0002-7461-9303
Timothy J. Miles: 0000-0001-7407-7404
Valerie Mizrahi: 0000-0003-4824-9115
John P. Overington: 0000-0002-5859-1064
Kevin D. Read: 0000-0002-8536-0130
Thomas Spangenberg: 0000-0002-5654-8919
Susan Wyllie: 0000-0001-8810-5605
Paul G. Wyatt: 0000-0002-0397-245X
Ian H. Gilbert: 0000-0002-5238-1314
Notes
The authors declare the following competing ﬁnancial
interest(s): M.J.L.-M. and T.J.M. are employees of GlaxoS-
mithKline. U.H.M. is an employee of Novartis Institutes for
BioMedical Research and a shareholder in Novartis. J.P. is an
employee of ViiV Healthcare and a shareholder in Glax-
oSmithKline. T.S. is an employee of Ares Trading SA, an aﬃliate
of Merck KGaA, Darmstadt, Germany. S.P.S.R. is an employee
of Novartis Institutes for BioMedical Research. W.V.V. is part
owner of ParaTheraTech LLC., a company that is developing
bumped-kinase inhibitors for use in animal health.
■ ACKNOWLEDGMENTS
The conference was in part supported by a Wellcome Trust
Centre Award 203134/Z/16/Z. We would also like to
acknowledge the following for providing travel bursaries to
allow scientists from Low and Middle Income Countries to
attend the meeting: the Bill & Melinda Gates Foundation
(OPP1199837); Medicines for Malaria Venture; Novartis
Institutes for Biomedical Research (NIBR); Drug for Neglected
Diseases initiative. We would also like to acknowledge Dr.
Catharine Goddard and Diane Purves for their huge eﬀorts in
organizing the conference and the help from the Administration
Team of the Division of Biological Chemistry and Drug
Discovery during the conference.
■ REFERENCES
(1) De Rycker, M., Baragana, B., Duce, S. L., and Gilbert, I. H. (2018)
Challenges and recent progress in drug discovery for tropical diseases.
Nature 559, 498−506.
(2) Manjunatha, U. H., and Smith, P. W. (2015) Perspective:
Challenges and opportunities in TB drug discovery from phenotypic
screening. Bioorg. Med. Chem. 23, 5087−5097.
(3) Sant’Anna, M. R., Diaz-Albiter, H., Aguiar-Martins, K., Al Salem,
W. S., Cavalcante, R. R., Dillon, V. M., Bates, P. A., Genta, F. A., and
Dillon, R. J. (2014) Colonisation resistance in the sand fly gut:
Leishmania protects Lutzomyia longipalpis from bacterial infection.
Parasites Vectors 7, 329.
(4) Molina, I., Gomez i Prat, J., Salvador, F., Trevino, B., Sulleiro, E.,
Serre, N., Pou, D., Roure, S., Cabezos, J., Valerio, L., Blanco-Grau, A.,
Sanchez-Montalva, A., Vidal, X., and Pahissa, A. (2014) Randomized
trial of posaconazole and benznidazole for chronic Chagas’ disease. N.
Engl. J. Med. 370, 1899−1908.
(5) Torrico, F., Gascon, J., Ortiz, L., Alonso-Vega, C., Pinazo, M. J.,
Schijman, A., Almeida, I. C., Alves, F., Strub-Wourgaft, N., Ribeiro, I.,
et al. (2018) Treatment of adult chronic indeterminate Chagas disease
with benznidazole and three E1224 dosing regimens: a proof-of-
concept, randomised, placebo-controlled trial. Lancet Infect. Dis. 18,
419−430.
(6) Cokol, M., Kuru, N., Bicak, E., Larkins-Ford, J., and Aldridge, B. B.
(2017) Efficient measurement and factorization of high-order drug
interactions in Mycobacterium tuberculosis. Sci. Adv. 3, No. e1701881.
ACS Infectious Diseases Viewpoint
DOI: 10.1021/acsinfecdis.9b00371
ACS Infect. Dis. 2020, 6, 3−13
11
(7)Moshynets, O. V., and Spiers, A. J. (2016) Viewing bioﬁlms within
the larger context of bacterial aggregations. In Bioﬁlms, pp 3−22,
InTech Press.
(8) Kotloff, K. L., Nataro, J. P., Blackwelder, W. C., Nasrin, D., Farag,
T. H., Panchalingam, S., Wu, Y., Sow, S. O., Sur, D., Breiman, R. F.,
Faruque, A. S. G., Zaidi, A. K. M., Saha, D., Alonso, P. L., Tamboura, B.,
Sanogo, D., Onwuchekwa, U., Manna, B., Ramamurthy, T., Kanungo,
S., Ochieng, J. B., Omore, R., Oundo, J. O., Hossain, A., Das, S. K.,
Ahmed, S., Qureshi, S., Quadri, F., Adegbola, R. A., Antonio, M.,
Hossain, M. J., Akinsola, A., Mandomando, I., Nhampossa, T., Acaćio,
S., Biswas, K., O’Reilly, C. E., Mintz, E. D., Berkeley, L. Y., Muhsen, K.,
Sommerfelt, H., Robins-Browne, R. M., and Levine, M. M. (2013)
Burden and aetiology of diarrhoeal disease in infants and young
children in developing countries (the Global EntericMulticenter Study,
GEMS): a prospective, case-control study. Lancet 382, 209−222.
(9) Acosta, A. M., Chavez, C. B., Flores, J. T., Olotegui, M. P., Pinedo,
S. R., Trigoso, D. R., Vasquez, A. O., Ahmed, I., Alam, D., Ali, A., Bhutta,
Z. A., Qureshi, S., Shakoor, S., Soofi, S., Turab, A., Yousafzai, A. K.,
Zaidi, A. K. M., Bodhidatta, L., Mason, C. J., Babji, S., Bose, A., John, S.,
Kang, G., Kurien, B., Muliyil, J., Raghava, M. V., Ramachandran, A.,
Rose, A., Pan, W., Ambikapathi, R., Carreon, D., Charu, V., Dabo, L.,
Doan, V., Graham, J., Hoest, C., Knobler, S., Lang, D., McCormick, B.,
McGrath, M., Miller, M., Mohale, A., Nayyar, G., Psaki, S., Rasmussen,
Z., Richard, S., Seidman, J., Wang, V., Blank, R., Gottlieb, M., Tountas,
K., Amour, C., Mduma, E., Ahmed, T., Ahmed, A. M. S., Dinesh, M.,
Tofail, F., Haque, R., Hossain, I., Islam,M.,Mahfuz,M., Chandyo, R. K.,
Shrestha, P. S., Shrestha, R., Ulak, M., Black, R., Caulfield, L., Checkley,
W., Chen, P., Kosek, M., Lee, G., Yori, P. P., Murray-Kolb, L., Schaefer,
B., Pendergast, L., Abreu, C., Binda, A., Costa, H., DiMoura, A., Filho, J.
Q., Leite, A., Lima, A., Lima, N., Lima, I., Maciel, B., Moraes, M., Mota,
F., Oria, R., Quetz, J., Soares, A., Svensen, E., Tor, S., Patil, C., Bessong,
P., Mahopo, C., Mapula, A., Nesamvuni, C., Nyathi, E., Samie, A.,
Barrett, L., Gratz, J., Guerrant, R., Houpt, E., Olmsted, L., Petri, W.,
Platts-Mills, J., Scharf, R., Shrestha, B., and Shrestha, S. K. (2014) The
MAL-ED study: a multinational and multidisciplinary approach to
understand the relationship between enteric pathogens, malnutrition,
gut physiology, physical growth, cognitive development, and immune
responses in infants and children up to 2 years of age in resource-poor
environments. Clin. Infect. Dis. 59 (Suppl 4), S193−S206.
(10) Van Voorhis, W. C., Doggett, J. S., Parsons, M., Hulverson, M. A.,
Choi, R., Arnold, S. L. M., Riggs, M. W., Hemphill, A., Howe, D. K.,
Mealey, R. H., Lau, A. O. T., Merritt, E. A., Maly, D. J., Fan, E., and Ojo,
K. K. (2017) Extended-spectrum antiprotozoal bumped kinase
inhibitors: A review. Exp. Parasitol. 180, 71−83.
(11) Hulverson, M. A., Choi, R., Arnold, S. L. M., Schaefer, D. A.,
Hemphill, A., McCloskey, M. C., Betzer, D. P., Muller, J., Vidadala, R. S.
R.,Whitman, G. R., Rivas, K. L., Barrett, L. K., Hackman, R. C., Love,M.
S., McNamara, C. W., Shaughnessy, T. K., Kondratiuk, A., Kurnick, M.,
Banfor, P. N., Lynch, J. J., Freiberg, G. M., Kempf, D. J., Maly, D. J.,
Riggs, M. W., Ojo, K. K., and Van Voorhis, W. C. (2017) Advances in
bumped kinase inhibitors for human and animal therapy for
cryptosporidiosis. Int. J. Parasitol. 47, 753−763.
(12) Huang, W., Hulverson, M. A., Choi, R., Arnold, S. L. M., Zhang,
Z., McCloskey, M. C., Whitman, G. R., Hackman, R. C., Rivas, K. L.,
Barrett, L. K., Ojo, K. K., Van Voorhis, W. C., and Fan, E. (2019)
Development of 5-Aminopyrazole-4-carboxamide-based Bumped-
Kinase Inhibitors for Cryptosporidiosis Therapy. J. Med. Chem. 62,
3135−3146.
(13) Manjunatha, U. H., Vinayak, S., Zambriski, J. A., Chao, A. T., Sy,
T., Noble, C. G., Bonamy, G. M. C., Kondreddi, R. R., Zou, B., Gedeck,
P., Brooks, C. F., Herbert, G. T., Sateriale, A., Tandel, J., Noh, S.,
Lakshminarayana, S. B., Lim, S. H., Goodman, L. B., Bodenreider, C.,
Feng, G., Zhang, L., Blasco, F., Wagner, J., Leong, F. J., Striepen, B., and
Diagana, T. T. (2017) A Cryptosporidium PI(4)K inhibitor is a drug
candidate for cryptosporidiosis. Nature 546, 376−380.
(14) Arnold, S. L. M., Choi, R., Hulverson, M. A., Schaefer, D. A.,
Vinayak, S., Vidadala, R. S. R., McCloskey, M. C., Whitman, G. R.,
Huang, W., Barrett, L. K., Ojo, K. K., Fan, E., Maly, D. J., Riggs, M. W.,
Striepen, B., and Van Voorhis, W. C. (2017) Necessity of Bumped
Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptospori-
dium Infection. J. Infect. Dis. 216, 55−63.
(15) Arnold, S. L. M., Choi, R., Hulverson, M. A., Whitman, G. R.,
McCloskey, M. C., Dorr, C. S., Vidadala, R. S. R., Khatod, M., Morada,
M., Barrett, L. K., Maly, D. J., Yarlett, N., and Van Voorhis, W. C.
(2019) P-glycoprotein mediated efflux reduces the in vivo efficacy of a
therapeutic targeting the gastrointestinal parasite Cryptosporidium. J.
Infect. Dis. 220, 1188.
(16) Schaefer, D. A., Betzer, D. P., Smith, K. D., Millman, Z. G.,
Michalski, H. C., Menchaca, S. E., Zambriski, J. A., Ojo, K. K.,
Hulverson, M. A., Arnold, S. L., Rivas, K. L., Vidadala, R. S., Huang, W.,
Barrett, L. K., Maly, D. J., Fan, E., Van Voorhis, W. C., and Riggs, M. W.
(2016) Novel Bumped Kinase Inhibitors Are Safe and Effective
Therapeutics in the Calf Clinical Model for Cryptosporidiosis. J. Infect.
Dis. 214, 1856−1864.
(17) Hulverson, M. A., Vinayak, S., Choi, R., Schaefer, D. A.,
Castellanos-Gonzalez, A., Vidadala, R. S. R., Brooks, C. F., Herbert, G.
T., Betzer, D. P., Whitman, G. R., Sparks, H. N., Arnold, S. L. M., Rivas,
K. L., Barrett, L. K., White, A. C., Jr., Maly, D. J., Riggs, M. W., Striepen,
B., Van Voorhis, W. C., and Ojo, K. K. (2017) Bumped-Kinase
Inhibitors for Cryptosporidiosis Therapy. J. Infect. Dis. 215, 1275−
1284.
(18) Lee, S., Ginese, M., Beamer, G., Danz, H. R., Girouard, D. J.,
Chapman-Bonofiglio, S. P., Lee, M., Hulverson, M. A., Choi, R.,
Whitman, G. R., Ojo, K. K., Arnold, S. L. M., Van Voorhis, W. C., and
Tzipori, S. (2018) Therapeutic Efficacy of Bumped Kinase Inhibitor
1369 in a Pig Model of Acute Diarrhea Caused by Cryptosporidium
hominis. Antimicrob. Agents Chemother. 62, e00147-18.
(19) Mor, S. M., Ascolillo, L. R., Nakato, R., Ndeezi, G., Tumwine, J.
K., Okwera, A., Sponseller, J. K., Tzipori, S., and Griffiths, J. K. (2018)
Expectoration of Cryptosporidium Parasites in Sputum of Human
Immunodeficiency Virus-Positive and -Negative Adults. Am. J. Trop.
Med. Hyg. 98, 1086−1090.
(20) Arez, F., Rebelo, S., Fontinha, D., Simaõ, D., Martins, T.,
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